NasdaqGS - Nasdaq Real Time Price USD
Vir Biotechnology, Inc. (VIR)
At close: 4:00 PM EST
After hours: 5:53 PM EST
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 4 | 9 | 9 |
| Avg. Estimate | -0.86 | -0.77 | -3.89 | -3.74 |
| Low Estimate | -0.96 | -0.84 | -4.02 | -5.28 |
| High Estimate | -0.66 | -0.68 | -3.62 | -2.75 |
| Year Ago EPS | -0.86 | -0.48 | -4.59 | -3.89 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 3 | 9 | 8 |
| Avg. Estimate | 8.14M | 18.21M | 68.36M | 30.36M |
| Low Estimate | -- | 5.74M | 61.8M | -- |
| High Estimate | 39.8M | 40.1M | 101.6M | 106.2M |
| Year Ago Sales | 16.79M | 11.71M | 86.18M | 68.36M |
| Sales Growth (year/est) | -51.50% | 55.50% | -20.70% | -55.60% |
Earnings History
| CURRENCY IN USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -1.01 | -1.05 | -0.89 | -1.05 |
| EPS Actual | -0.86 | -0.48 | -1.02 | -1.56 |
| Difference | 0.15 | 0.57 | -0.13 | -0.51 |
| Surprise % | 14.90% | 54.30% | -14.60% | -48.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.86 | -0.77 | -3.89 | -3.74 |
| 7 Days Ago | -0.89 | -0.83 | -3.39 | -3.77 |
| 30 Days Ago | -0.89 | -0.83 | -3.39 | -3.77 |
| 60 Days Ago | -0.89 | -0.83 | -3.39 | -3.77 |
| 90 Days Ago | -0.89 | -0.79 | -3.35 | -3.74 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 4 | 3 | 1 | 3 |
| Up Last 30 Days | 5 | 3 | 1 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | -- | 6 | 6 |
Growth Estimates
| CURRENCY IN USD | VIR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 0.00% | -- | -- | 5.50% |
| Next Qtr. | -60.40% | -- | -- | 11.40% |
| Current Year | 15.30% | -- | -- | 2.10% |
| Next Year | 3.90% | -- | -- | 12.30% |
| Next 5 Years (per annum) | 7.00% | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Maintains | Barclays: Overweight to Overweight | 11/4/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/4/2024 |
| Reiterates | Needham: Buy to Buy | 11/1/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/20/2024 |
| Maintains | Barclays: Overweight to Overweight | 8/2/2024 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 6/6/2024 |
Related Tickers
APLS Apellis Pharmaceuticals, Inc.
28.83
+2.69%
ATHA Athira Pharma, Inc.
0.7000
-6.67%
MDGL Madrigal Pharmaceuticals, Inc.
338.22
+0.18%
ZNTL Zentalis Pharmaceuticals, Inc.
3.8400
+1.59%
TOVX Theriva Biologics, Inc.
1.9700
0.00%
EPIX ESSA Pharma Inc.
1.7100
+0.59%
SAGE Sage Therapeutics, Inc.
5.95
+0.17%
ALNY Alnylam Pharmaceuticals, Inc.
273.01
+2.91%
BEAM Beam Therapeutics Inc.
26.62
+11.24%
LXRX Lexicon Pharmaceuticals, Inc.
1.2100
+1.68%